CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Y371H (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Crenolanib + PRT062607
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Crenolanib resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
PRT062607 + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Vanflyta (quizartinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin + PRT062607
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin + PRT062607
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Entospletinib + Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of Entospletinib to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
PRT062607 + Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Q365_E366insSK (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin + PRT062607
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
PRT062607 + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Vanflyta (quizartinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Gilteritinib + PRT062607
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Xospata (gilteritinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
PRT062607 + Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Q365_E366insSK FLT3 pos
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).
|
31943762
|
CBL Y371H FLT3 pos
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).
|
31943762
|
CBL Y371del FLT3 pos
|
hematologic cancer
|
sensitive
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).
|
31943762
|